Investigating blood proteins related to heart failure
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
UConn Health · NCT00762008
This study is trying to see if two specific proteins in the blood can help identify when people with heart failure are having a worsening episode.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UConn Health (other) |
| Locations | 1 site (Farmington, Connecticut) |
| Trial ID | NCT00762008 on ClinicalTrials.gov |
What this trial studies
This research aims to identify whether two specific proteins in the blood are elevated during episodes of acute heart failure. These proteins are produced when the heart's function deteriorates, and their levels may indicate the transition from compensated hypertrophy to acute heart failure. The study will analyze blood samples from individuals with heart failure and healthy controls to establish a correlation between protein levels and heart failure symptoms. By understanding these biomarkers, the research seeks to improve early detection and prevention strategies for heart failure.
Who should consider this trial
Good fit: Ideal candidates include individuals over 18 years with stable or decompensated heart failure symptoms, as well as healthy individuals without a history of heart issues for comparison.
Not a fit: Patients who have undergone recent cardiac or non-cardiac surgery or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of heart failure, potentially reducing morbidity and mortality.
How similar studies have performed: While the study explores a novel approach to identifying biomarkers for heart failure, previous studies have shown the importance of biomarkers like BNP in heart failure diagnosis, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged \>18yrs * stable or decompensated heart failure, irrespective of LVEF * decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites * Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures) * Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls. Exclusion Criteria: * Subjects who are unable to give informed consent * Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment * Pregnant subjects are not excluded
Where this trial is running
Farmington, Connecticut
- University of Connecticut Health Center — Farmington, Connecticut, United States (RECRUITING)
Study contacts
- Principal investigator: Bruce T. Liang, M.D. — UConn Health
- Study coordinator: Fahad E Shah
- Email: fshah@uchc.edu
- Phone: 860-679-2692
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Decompensated Heart Failure, Heart Failure, biomarkers